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HMG I/Y appears to be a multifunctional protein that relies on in its ability to interact with DNA in a
structure-speciﬁc manner and with DNA, binding transcriptional activators via distinct protein-protein inter-
action surfaces. To investigate the hypothesis that HMG I/Y may have a role in human immunodeﬁciency virus
type 1 (HIV-1) expression, we have analyzed whether HMG I/Y interacts with the 5* long terminal repeat and
whether this interaction can modulate transcription factor binding. Using puriﬁed recombinant HMG I, we
have identiﬁed several high-afﬁnity binding sites which overlap important transcription factor binding sites.
One of these HMG I binding sites coincides with an important binding site for AP-1 located downstream of the
transcriptional start site, in the 5* untranslated region at the boundary of a positioned nucleosome. HMG I
binding to this composite site inhibits the binding of recombinant AP-1. Consistent with this observation, using
nuclear extracts prepared from Jurkat T cells, we show that HMG I (but not HMG Y) is strongly induced upon
phorbol myristate acetate stimulation and this induced HMG I appears to both selectively inhibit the binding
of basal DNA-binding proteins and enhance the binding of an inducible AP-1 transcription factor to this AP-1
binding site. We also report the novel ﬁnding that a component present in this inducible AP-1 complex is
ATF-3. Taken together, these results argue that HMG I may play a fundamental role in HIV-1 expression by
determining the nature of transcription factor-promoter interactions.
It is ﬁrmly established that chromatin (histones plus a wealth
of nonhistone proteins of largely unknown function) plays a
fundamental role in regulating the transcriptional activity of a
gene by establishing highly specialized structures that can ei-
ther promote or inhibit transcription factor binding. How such
specialized structures, including the role of many well-charac-
terized nonhistone proteins, are established to regulate the
transcription process is poorly understood.
One important function of chromatin is to repress inappro-
priate transcription in either a reversible or permanent manner
(48). This is achieved by compacting eukaryotic DNA, in a
hierarchical fashion, into inaccessible complex three-dimen-
sional structures. For transcription to occur, histone-DNA in-
teractions in underlying nucleosomes must be disrupted to
enable the binding of transcriptional activators to important
regulatory elements. This appears to be achieved in a number
of different ways. Large chromatin remodeling machines exist
in the nucleus of eukaryotic cells that can, in an ATP-depen-
dent manner, facilitate transcription factor binding (35). Post-
translational modiﬁcation of histones, like histone acetylation,
also plays an essential role in the gene activation process (28).
The existence of cofactors that can increase the afﬁnity and
stability of transcriptional activators for their DNA binding site
provides an alternative strategy by which DNA-binding pro-
teins can effectively compete with histones for naked DNA.
The ability of HMG I/Y to stimulate the DNA-binding activity
of a wide variety of promoter-speciﬁc activators indicates that
these chromatin-associated proteins may play such a role.
HMG I and Y are isoforms which are produced by alterna-
tive splicing, whereas the other member of the family, HMG
I-C, is expressed as a separate gene product (6). HMG I/Y can
directly interact via protein-protein interactions, employing
different interaction surfaces, with a number of different tran-
scriptional activators, including NF-kB (42, 50, 51), ATF-2
(13), SRF (8), NF-Y (10), Oct 2A (1), Elf (24), and c-Rel (22),
increasing their afﬁnity for DNA. Typically, target genes for
this HMG I/Y enhancement of factor binding are inducible
and include genes for cytokines such as beta interferon (42),
interleukin-2 receptor a chain (24), E-selectin (30), interleu-
kin-2, and macrophage colony-stimulating factor (22). More
recently, it was also shown that expression of the nitric oxide
synthase gene may be regulated by HMG I/Y (36). Enhance-
ment of factor binding, in some cases, also requires interaction
of HMG I/Y with DNA. One explanation for this ﬁnding is that
the ability of HMG I/Y to bend DNA may create a more
favorable DNA conformation for factor binding (15). For the
beta interferon promoter, higher-order transcription factor
complex formation can be further stabilized by HMG I/Y-
factor interactions (14). Paradoxically, in the case of NF-kB,
the protein-interacting domain of HMG I/Y includes part of
the same domain that interacts with DNA (51). The biological
importance of HMG I/Y in regulating gene expression is fur-
ther implied by the ﬁnding that the expression of HMG I/Y is
upregulated in rapidly proliferating cells, including early em-
bryonic cells (7) and neoplastic tissues (19, 25).
HMG I/Y is characterized by three tandemly organized basic
DNA-binding modules separated by a ﬂexible linker; each in-
dividual module is capable of interacting with the minor groove
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10523of DNA in a structurally speciﬁc manner, with the second basic
repeat being responsible for high-afﬁnity binding (4, 18, 49,
51). These consensus basic repeats adopt a deﬁned crescent-
shaped planar structure, resembling the drugs netropsin and
distamycin (6). These basic DNA-binding modules are referred
to as AT-hooks because in most cases, but not all, they pref-
erentially bind to the minor groove of AT-rich sequences (6).
These proteins can also bind, with high afﬁnity, to non-B-form
DNA, such as synthetic four-way junctions and supercoiled
plasmid substrates (6, 21, 34). These binding characteristics
support the proposal that HMG I/Y may have additional roles
in other DNA-dependent processes.
All stages of the human immunodeﬁciency virus type 1
(HIV-1) life cycle are dependent on host-speciﬁc cellular fac-
tors. Recently, HMG I/Y was shown to be a host-speciﬁc fac-
tor required for the integration of HIV-1 preintegration com-
plexes (16, 23). To investigate the possibility that HMG I/Y
may also be involved in HIV-1 transcription, we have analyzed
the interaction of HMG I/Y with the viral long terminal repeat
(LTR) using puriﬁed recombinant proteins and nuclear ex-
tracts prepared from living cells. We ﬁnd that HMG I/Y can
function to modulate both the efﬁciency and selectivity of AP-1
binding to HIV-1 promoter DNA. These results suggest that
HMG I/Y may play an important role at all key stages in the
life cycle of HIV-1.
MATERIALS AND METHODS
Protein puriﬁcation and nuclear extract preparation. Recombinant HMG I
and the DNA-binding mutant form of HMG I were puriﬁed as described (39).
This mutant form has four proline-to-alanine substitutions introduced at residues
57 and 61 (located in DNA-binding domain 2) and at residues 83 and 87 (located
in DNA-binding domain 3). Freeze-dried proteins were resuspended in buffer A
(20 mM HEPES [pH 7.9], 100 mM NaCl, 10% [vol/vol] glycerol, 1 mM dithio-
threitol, 0.1% NP-40). His-tagged c-Fos and c-Jun (33) were puriﬁed by the
method described by Thanos and Maniatis (43). To make the Fos-Jun hetero-
dimer, equimolar quantities of c-Fos and c-Jun were codialyzed against buffer A.
Typically, the ﬁnal concentration of Fos-Jun was around 300 ng/ml. Individual
preparations varied considerably in terms of DNA-binding activity, with usually
less than 10% of the total protein being active (33). As shown in Fig. 3A, maximal
binding to site AP1-3 was achieved with 300 ng of total protein. Nuclear extracts
were made from Jurkat T cells according to the method described earlier (11).
Half the cells were induced for 2 h, prior to harvesting, with phorbol ester 12-
myristate 13-acetate (PMA). To separate HMG I from the bulk of nuclear pro-
teins, nuclear proteins were precipitated using 60% ammonium sulfate. The
supernatant and the nuclear precipitate were dialyzed against buffer D (100 mM
KCl) (11). It is worth noting that among the different nuclear extract prepara-
tions used (this investigation used four different preparations), the DNA-protein
complexes produced did not differ qualitatively but differences occurred quan-
titatively.
Gel mobility shift assays. The mobility shift assays were carried out as de-
scribed previously (33). The oligonucleotide used in gel mobility shift assays
was 59-CCCTTTTAGTCAGTGTGGAAAATCT-39. The ﬁnal buffer (buffer R)
contained 6 mM HEPES (pH 7.9), 10 mM Tris (pH 8.0), 1 mM MgCl2,1m M
EDTA (pH 8.0), 10 mM dithiothreitol, 5% glycerol, 1% sucrose, 0.1% NP-40,
and 40 mM NaCl in a ﬁnal volume of 20 ml. In the case of DNA-binding reactions
using nuclear extracts, KCl replaced NaCl. Poly(dG-dC) and/or poly(dI-dC)
(Amersham-Mannheim) were also included in reactions using both recombinant
proteins (100 ng) and nuclear extracts (2 mg). Reactions were run on preelec-
trophoresed 4.5% nondenaturing polyacrylamide gels (0.53 Tris-borate-EDTA
[TBE]) at 15 V/cm (4°C). Gels were dried, exposed to X-ray ﬁlm, and quantitated
by phosphoimaging.
DNase I footprinting assays. DNase I footprinting analysis was carried out as
described previously (33). DNA-binding reactions were carried out as for gel
shift assays. Two PCR primers, upstream HIV-LTR (2187 to 115) and down-
stream HIV-LTR (25t o1230), were synthesized with restriction sites at both
ends to allow footprinting on both strands. Typically, 0.05 U of DNase I (Boehr-
inger-Mannheim) was used in reactions involving puriﬁed recombinant proteins.
Puriﬁed digestion products were run ona7Murea–8% polyacrylamide gel (13
TBE) at 40 V/cm, transferred to DEAE paper (Whatman), dried, and exposed to
X-ray ﬁlm or to a phosphoimage screen.
Western blotting and immunoprecipitation. For Western blot analysis of
HMG I/Y in nuclear extracts, afﬁnity-puriﬁed rabbit polyclonal antibodies were
used following the method described by Reeves and Nissen (39). Immunopre-
cipitation of HMG I/Y in nuclear extracts was carried out using the method
described before (12). Typically, 8.5 mg of antibody was added to 100 mlo f
nuclear extract (7.5 mg/ml). Immunodepletion of HMG I/Y was conﬁrmed by
Western blot and gel shift analyses. AP-1/cyclic AMP response element binding
protein (CREB) antibodies were purchased from Santa Cruz Biotechnology and
used according to their instructions.
Immobilized-template assays. Dynabeads (M280 streptavidin; Dynal) (200 mg)
were washed twice in buffer T (10 mM Tris [pH 7.5], 1 mM EDTA, 1 M NaCl).
Beads were then resuspended in 20 ml of buffer T containing 10 pmol of biotin-
ylated oligonucleotide probe and agitated gently at room temperature for 30 min.
After washing several times in buffer T to remove any unbound probe, beads
were equilibrated in buffer R for 20 min. The magnetic beads were concentrated
in a magnetic particle concentrator (Dynal) before being resuspended in buffer
R containing 250 mg of nuclear protein and 40 ng of poly(dG-dC) per ml in a ﬁnal
volume of 120 ml and agitated gently for 20 min at room temperature. Binding
reactions were then washed three times in buffer R containing 10 ng of poly(dG-
dC) per ml before the beads were concentrated and resuspended in sodium
dodecyl sulfate (SDS) loading dye, loaded on SDS–12% polyacrylamide gel
electrophoresis (PAGE) gels, and electrophoresed at 15 V/cm for 1.5 h.
RESULTS
Characterization of HMG I/Y binding sites within the 5*-
UTR of the HIV-1 promoter. To begin to address the question
of whether HMG I/Y may have a functional role in HIV-1
expression, we ﬁrst examined whether these chromosomal pro-
teins can interact with the LTR by determining the location of
potential HMG I/Y binding sites using the DNase I footprint-
ing assay. The region of the LTR that we focused on centred
around the transcriptional initiation site (2187 to 1230). This
is a particularly interesting region of the promoter, which in-
cludes part of the 59-UTR, because it contains a number of
important regulatory elements that bind both inducible and
constitutive transcription factors essential for efﬁcient viral
transcription and replication (2, 47). In addition, the 59-UTR
interacts with a speciﬁcally positioned nucleosome that is dis-
placed or disrupted upon transcriptional activation (46). It is
believed that the binding of AP-1 to the 59-UTR may be in-
volved in this disruption process (33, 47).
Representative footprints are shown in Fig. 1A to C, and a
summary of the position of both high- and low-afﬁnity HMG
I/Y binding sites is shown in Fig. 2. In these experiments, highly
puriﬁed recombinant HMG I was used (Fig. 1D); identical
results were obtained with recombinant HMG Y (data not
shown). Figure 1A displays high-afﬁnity (footprint region 3)
and low-afﬁnity (footprint region 2) binding sites. The entire
HMG I/Y footprinted region can extend over relatively large
DNA distances (over 30 bp) because they are a composite of
smaller individual footprints which reﬂect the binding of indi-
vidual AT-hooks to DNA. The binding of at least two AT-hook
peptide motifs is required for high-afﬁnity binding (see Intro-
duction). Figures 1B and C also displays high-afﬁnity binding
sites (footprint regions 5 and 3, respectively); only 5 ng of
protein (21 nM) is required to produce a clear protected re-
gion.
The positions of these and other characterized footprints are
located at potentially signiﬁcant regions (Fig. 2). In other re-
ported examples, typically HMG I/Y binds to sites that lie
adjacent to or are part of a transcription factor binding site
(see Introduction). Footprint region 5 overlaps an AP-1 and an
NF-AT site, while footprint regions 1, 2, and 3 overlap binding
sites for USF, NF-kB, and TATA-binding protein (TBP), re-
spectively. Interestingly, footprint region 4 is located at or near
the dyad of the positioned nucleosome, whereas footprint re-
gions 3 and 5 are located at the boundaries. To begin an
investigation of whether these HMG binding sites may have a
biological function, in this study we have focused on whether
the binding of HMG I to footprint region 5 can regulate the
binding of AP-1.
HMG I can inhibit the binding of Fos-Jun. The 59-UTR of
the HIV-1 promoter contains three AP-1 binding sites (AP1-1,
10524 HENDERSON ET AL. J. VIROL.AP1-2, and AP1-3) (Fig. 2). The ﬁrst two sites are located
within the positioned nucleosome, whereas the third site is
located at the boundary. Given that the binding site for HMG
I and this third AP-1 binding site overlap (footprint region 5),
the effect of HMG I binding on the binding of Fos-Jun to this
site was analyzed by carrying out a Fos-Jun titration in both the
presence and absence of HMG I. Figure 3A clearly shows that
the binding of HMG I to the labeled probe inhibits the binding
of Fos-Jun to site AP1-3 (compare lanes 5 to 7 with lanes 2 to
4). We estimate that a 5- to 10-fold molar excess of HMG I is
required to inhibit Fos-Jun binding by more than 80%. Fur-
thermore, this inhibition of Fos-Jun binding is dependent on
the ability of HMG I to bind to DNA, because when we used
a DNA-binding mutant, this inhibition of binding was no
longer observed (compare lanes 8 to 10 with lanes 5 to 7).
To conﬁrm that this observed inhibition of Fos-Jun binding
was due to speciﬁc HMG I binding, the binding site of HMG
I was mutated, and this probe was used in DNA-binding assays.
The mutation involved changing two A residues that lie imme-
diately outside the core AP-1 binding site to C residues (TTT
TAGTCAG to CCTTAGTCAG), (Fig. 2). Figure 3B shows
that this mutation markedly inhibits HMG I binding to the
FIG. 1. 59-UTR of the HIV-1 promoter contains multiple high-afﬁnity HMG I binding sites. To determine the location of potential HMG I binding sites, DNase
I footprinting reactions were carried out as described in the text. Analysis of three segments within the 59-UTR is shown. These include regions 2105 to 11 (A), 156
to 1128 (B), and 1112 to 1194 (C). The numbering is relative to the start site of transcription at 11. Solid boxes represent high-afﬁnity binding sites, whereas shaded
boxes illustrate the position of low-afﬁnity HMG I binding sites. Since HMG I contains three distinct individual DNA-binding domains, each capable of producing a
small footprint, the combination of these individual footprints has been described as a footprint region. (D) SDS–15% polyacrylamide gel showing 2 mg of recombinant
HMG I.
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inhibition of Fos-Jun binding is no longer observed (compare
lanes 11 and 12 with 5 and 6). Importantly, this mutation does
not alter the binding of Fos-Jun (compare lane 10 with 4).
These results have also been veriﬁed by using DNase I foot-
printing assays (data not shown). We therefore conclude that
the binding of HMG I and Fos-Jun to this composite site is
mutually exclusive. It is also worth noting that changing these
two T residues to G residues alters the mobility of the free
probe, implying that these T residues may be involved in DNA
bending.
Interaction between endogenous HMG I and the 5*-UTR.
Next, we investigated whether the binding by HMG I to the
composite site AP1-3 (footprint region 5) could be reproduced
in a complex nuclear protein extract prepared from living cells.
Given that phorbol esters can dramatically induce HIV-1 tran-
scription (46), we addressed the question of whether HMG I/Y
may be involved in this induction process by examining wheth-
er HMG I/Y present in PMA-induced Jurkat nuclear extracts
can interact with site AP1-3. To study this possibility, gel mo-
bility shift assays were performed using the same labeled probe
as used in Fig. 3A.
Figure 4A shows that, because HMG I/Y is a minor groove
DNA-binding protein, an interaction between HMG I/Y and
DNA in nuclear extracts is observed but only when poly(dG-
dC) and not poly(dI-dC) is used as competitor DNA in binding
reactions. Most signiﬁcantly, the speciﬁc association of HMG
I/Y with site AP1-3 when poly(dG-dC) instead of poly(dI-dC)
is used is correlated with the generation of a completely new
protein-DNA binding proﬁle (compare lanes 8 to 10 with lanes
3 to 5 in panel A of Fig. 4).
Figure 4 also clearly shows a broad band that runs in the
same position as an HMG I/Y-DNA complex in the induced
extract but not in the uninduced extract (compare lanes 8 to 10
in panel A and lanes 2 to 4 in panel B with lanes 6 to 8 in panel
B). Conﬁrmation that this protein-DNA complex indeed con-
tains HMG I/Y is shown in Fig. 4C. With the mutated HMG
binding site used as a labeled probe at relatively high concen-
trations of nuclear extract, HMG I/Y binding is no longer
observed (compare lanes 7 and 8 with lanes 2 and 3). It is worth
noting that at the high nuclear extract concentrations used in
this experiment, complex 2 is not seen (compare lane 4 with
lane 2 in Fig. 4B). At even higher concentrations of nuclear
extract, in the absence of HMG I/Y binding, nonspeciﬁc DNA-
binding proteins like histones associate with the DNA probe
(data not shown and lanes 9 and 10 in panel C). The conclusion
that endogenous HMG I/Y binds to site AP1-3 is also sup-
ported by immunoprecipitation experiments (see below). At
this stage we do not know why HMG I/Y protein-DNA com-
plexes migrate as a diffuse band, but one possibility is that
HMG I and HMG Y may be heavily modiﬁed in these extracts
(see Discussion).
In addition to HMG I-DNA complexes, three additional
protein-DNA complexes are observed when induced nuclear
extracts are used. Complexes 1, 2, and 4 are also observed
when uninduced extracts are employed, implying that these
DNA-binding proteins are basal factors. On the other hand,
AP-1 complex 3 is speciﬁcally induced upon PMA induction
(compare lanes 1 to 4 with lanes 5 to 8 in Fig. 4B). We con-
clude that previous studies that have used poly(dI-dC) in their
binding reactions have potentially missed important factor-
DNA interactions at the 59-UTR of the HIV-1 promoter (45).
Mutation of the HMG binding site not only inhibits HMG
I/Y binding, but also abolishes the formation of the inducible
AP-1 complex 3 and to a lesser extent complex 1 (compare
lanes 7 and 8 with lanes 2 and 3 in Fig. 4C). Therefore, it is
possible that, in contrast to the results in Fig. 3B, this mutation
not only inhibits HMG I/Y binding but may also inhibit the
formation of these nucleoprotein complexes, perhaps by alter-
ing the DNA-bending properties of the DNA fragment. Since
the formation of inducible complex 3 correlates with the bind-
ing of HMG I/Y, the following experiments were designed to
examine the interplay between HMG I/Y binding and complex
FIG. 2. Summary of the positions of HMG I binding sites within the 59-LTR. Shown is the sequence of the 59-LTR from 2187 to 1230. Previously identiﬁed
transcription factor binding sites are also shown (2, 44). Solid and hatched rectangles below the sequence represent high- and low-afﬁnity binding sites for HMG I,
respectively. The shaded region (110 to 1155) indicates the approximate location of the positioned nucleosome identiﬁed by in vivo footprinting (43). The three AP-1
binding sites within this nucleosome are labeled AP1-1, AP1-2, and AP1-3. The two T residues that were mutated to G residues in footprint region 5 are highlighted
with stars. Bracketed is the DNA probe used for gel shift analysis. R, start site of transcription.
¿
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binding (Fig. 3A) has a role in this process.
HMG I is induced upon PMA stimulation. The results in
Fig. 4 indicate that HMG I/Y associates with site AP1-3 upon
PMA induction. To investigate this further, a Western blot
analysis was carried out examining the abundance of HMG I
and HMG Y in uninduced and induced Jurkat extracts (Fig.
5A) (the SDS protein gel above the Western blot demonstrates
that appropriate induced and uninduced lanes received an
equivalent amount of protein; see the ﬁgure legend). Most
interestingly, HMG I is markedly induced (about ﬁvefold),
whereas the induction of HMG Y was modest (compare lane
2 with lane 3 and lane 6 with lane 7). In an attempt to separate
HMG I/Y from the bulk of nuclear protein, (NH4)2SO4 was
added to the nuclear extract (ﬁnal concentration, 60%). Most
unexpectedly, HMG I fractionated to the supernatant, whereas
HMG Y was precipitated with the bulk of nuclear protein
(compare lanes 5 and 6 with lanes 3 and 4).
Having separated HMG I from HMG Y, it was of interest to
investigate whether the HMG binding observed in unfraction-
ated nuclear extracts (Fig. 4A) was due to the interaction of
HMG I or HMG Y, or both, to site AP1-3. DNA-binding
assays were carried out using induced and uninduced nuclear
pellet and supernatant fractions, and the protein-DNA com-
plexes formed were analyzed by mobility gel shift assays. Fig-
ure 5B clearly shows that HMG I present in the induced
supernatant fraction can bind strongly to the labeled probe.
Very little binding is observed in the uninduced supernatant
fraction (compare lanes 12 to 15 with lanes 16 to 19). Inter-
estingly, HMG Y present in the induced nuclear pellet fraction
does bind to the labeled DNA fragment (lanes 2 to 6). We
therefore conclude that HMG I is responsible for the binding
observed in unfractionated nuclear extracts. Figure 5B also
shows that basal complex 1 and a new complex (which migrates
faster than complex 3) are also present in the supernatant
fractions.
HMG I can selectively determine which nuclear DNA-bind-
ing protein binds to the 5*-UTR. The above results have clearly
demonstrated that using recombinant proteins, HMG I can
inhibit AP-1 binding to site AP1-3 on the 59-UTR (Fig. 3). On
the other hand, using induced Jurkat nuclear extracts, an in-
ducible AP-1 factor can bind to DNA in the presence of HMG
I (Fig. 4). An attractive hypothesis that can reconcile these
observations is that the induced HMG I can both selectively
inhibit the binding of basal DNA-binding proteins (which are
present in both uninduced and induced nuclear extracts) and
promote the binding of the inducible AP-1 transcription factor.
To test this hypothesis, we took advantage of our ability to
separate HMG I from the inducible AP-1 complex (Fig. 5A). A
titration was performed in which HMG I, present in the
(NH4)2SO4 supernatant fraction, was added to a constant
amount of precipitated nuclear protein which contains the
PMA-inducible AP-1 factor (complex 3) (Fig. 6B). The super-
natant fraction was immunoprecipitated with either HMG I
antibodies or control antibodies against histone H2A.
Figure 6A shows that HMG I/Y immunodepletion, and not
mock or immunodepletion of H2A, of the induced supernatant
fraction removes only HMG I and not the other DNA-binding
proteins present in this fraction, including basal factor 1. Lane
2 of Fig. 6B shows the formation of basal complex 2 and the
FIG. 3. HMG I inhibits the binding of Fos-Jun to site AP1-3. (A) To examine the effect of HMG I on the binding of Fos-Jun to site AP1-3, a Fos-Jun titration (see
Materials and Methods) was carried out in which either no protein, 25 ng of HMG I, or 25 ng of a mutant DNA-binding form of HMG I (mHMG I) was added to
binding reactions containing a 25-bp probe. (B) The experiment in panel A was repeated except that the HMG I/Y binding site was mutated. Lanes 2, 5, 8, and1 1
received 12 ng of HMG I, while lanes 3, 6, 9, and 12 received 25 ng of HMG I.
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fraction. When control immunodepleted supernatant (contain-
ing HMG I) is titrated back to the (NH4)2SO4-precipitated
fraction, at the lowest concentration of supernatant, formation
of basal complex 2 is inhibited (compare lane 3 with lane 2). As
the concentration of HMG I is increased in the binding reac-
tion, the formation of inducible AP-1 complex 3 is enhanced.
Concurrently, the production of basal complex 1 is also ob-
served (this is because this basal factor is present in the super-
natant fraction). This binding proﬁle mimics the situation
FIG. 4. Endogenous HMG I binds to site AP1-3. (A) DNA-binding reactions were carried out using a labeled probe containing site AP1-3 and increasing amounts
of a nuclear extract (NE) prepared from PMA-induced Jurkat cells. As indicated, reactions received either poly(dI-dC) or poly(dG-dC) (2 mg). Lanes 2 and 7, 3 and
8, 4 and 9, and 5 and 10 received 1, 5, 10, and 20 mg of nuclear extract, respectively. A mobility gel shift assay was performed to identify assembled nucleoprotein
complexes. (B) DNA-binding reactions, as indicated, were carried out using nuclear extracts prepared from uninduced and PMA-induced Jurkat cells. The nucleo-
protein complexes generated are shown as complexes 1 to 4. The formation of HMG I-DNA complexes is also highlighted. Lanes 1 and 5, 2 and 6, 3 and 7, and 4 and
8 received 2, 5, 10, and 15 mg of nuclear extract, respectively. (C) Mobility gel shift assay was carried out using labeled DNA probes that contained either a mutated
or an unmodiﬁed HMG I/Y binding site. Lanes 2 to 5 and lanes 7 to 10 received 15, 20, 25, and 30 mg of nuclear extract, respectively.
10528 HENDERSON ET AL. J. VIROL.when the unfractionated nuclear extract is used in binding
reactions (compare lane 7 of Fig. 6B with lane 4 of Fig. 4B).
Strikingly, when HMG I is immunodepleted, the production
of the inducible AP-1 complex 3 is markedly reduced, while the
formation of basal complex 1 is enhanced (Fig. 6B, compare
lanes 9 to 12 with lanes 4 to 7). This result clearly shows that
the inducible AP-1 factor is in competition with the basal
DNA-binding protein for the same binding site and that HMG
I selectively facilitates the formation of the inducible AP-1–
DNA complex. This result can also be mimicked when the
uninduced supernatant fraction is added back (data not
shown). In addition, at the lowest concentration of HMG I-
depleted supernatant added, the formation of basal complex 2
is no longer inhibited (compare lane 8 with lane 3). However,
as the concentration of the HMG I-immunodepleted superna-
tant increases, basal factor 1 outcompetes basal factor 2 for
DNA binding. Clearly, there is a complex interplay between
the inducible AP-1 factor, the different basal factors, and
HMG I for DNA binding, but this result clearly shows that in
this complex mixture of proteins, HMG I selectively enhances
the binding of the inducible AP-1 factor to site AP1-3.
To conﬁrm that HMG I can indeed inhibit the DNA-binding
activity of basal factor 2, an HMG I titration was carried out in
which recombinant HMG I was added to uninduced nuclear
precipitated extracts. Lane 2 of Fig. 6C shows the formation of
DNA-protein complexes 2 and 4. As increasing amounts of
HMG I are added to the binding reactions, formation of both
of these complexes is inhibited, which coincides with the bind-
ing of HMG I to the labeled probe. This result clearly shows
that HMG I can inhibit the binding not only of recombinant
AP-1, but also of basal DNA-binding proteins present in un-
induced nuclear extracts. Taken together, these results support
the above hypothesis by showing that HMG I can both inhibit
and facilitate factor binding in a selective manner and provide
a potential mechanism for how this nonhistone chromosomal
protein may play an important role in HIV-1 expression by
determining which transcription factor associates with impor-
tant DNA regulatory elements.
PMA-inducible AP-1 complex contains ATF-3. Having de-
termined that HMG I plays an important role in facilitating the
binding of inducible AP-1 complex 3 to DNA, the next impor-
tant question to be addressed was to identify the key AP-1
components present in this inducible complex. Previously, it
was reported that by employing supershift assays using anti-
bodies raised against different AP-1 members, c-Fos, Jun D,
CREB, ATF-1, and ATF-2 interacted with site AP1-3 (37, 38).
However, employing this assay, we were unable to reproduce
these results. Furthermore, close examination of these re-
ported studies revealed that these transcription factors are only
minor components of the inducible complex. We therefore
adopted an alternative approach to determine the major com-
ponents of this inducible complex. Biotinylated site AP1-3 was
incubated with PMA-induced and uninduced nuclear extracts
under the same conditions as used for gel shift experiments
(Fig. 4). The DNA-bound transcription factors were then pu-
riﬁed from the bulk of nuclear proteins by using magnetic
streptavidin beads (Fig. 7B). After several washes with binding
buffer, the isolated DNA-bound proteins were eluted from the
DNA and analyzed by Western blotting using a battery of
different ATF/CREB family members (Fig. 7A). In crude nu-
clear extracts, all of the tested ATF/CREB family members
were present. As expected, treatment of Jurkat T cells with
PMA, under the conditions used here, induced the synthesis of
c-Fos, CREB-1, c-Jun, and ATF-3. Most interestingly, neither
CREB-1, c-Jun, nor c-Fos was puriﬁed by site AP1-3 attached
to magnetic streptavidin beads. On the other hand, we ﬁnd that
ATF-3 is the major component puriﬁed from the crude nuclear
extract. A minor component that binds to site AP1-3 is ATF-2.
Importantly, as a control, these transcription factors were not
detected when magnetic beads alone were incubated with nu-
clear extracts (data not shown). The speciﬁcity of this assay is
also highlighted by the observation that despite a strong anti-
FIG. 5. PMA induction of Jurkat T cells induces HMG I. (A) Nuclear extract (NE) proteins prepared from uninduced and PMA-induced Jurkat T cells were
precipitated using 60% (NH4)2SO4 (see Materials and Methods). Western blot analysis of precipitated and supernatant fractions was carried out using afﬁnity-puriﬁed
polyclonal antibodies raised against HMG I/Y. Lanes 2 to 5 and 6 and 7 received 40 and 10 mg of total protein, respectively. (B) Mobility gel shift assay carried out
using site AP1-3 and (NH4)2SO4-precipitated (ppt) and supernatant (supern.) fractions derived from uninduced and induced nuclear extracts. Lanes 2 to 6 and 7 to
11, received 1, 2, 5, 10, and 15 mg of total protein, respectively. Lanes 12 to 15 and 16 to 19 received 2, 5, 10, and 15 mg of total protein, respectively.
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bind to the puriﬁed DNA probe. In addition to ATF-3, Fig. 7B
shows that Fra-1 is a factor present in uninduced nuclear ex-
tracts which binds strongly to site AP1-3. Under the induction
conditions used here, the level of DNA binding does not
change between the induced and uninduced states.
DISCUSSION
The focus of this study was to examine whether HMG I can
interact with an important regulatory region in the HIV-1
promoter, the 59-UTR, and whether this interaction could play
a role in modulating the binding of AP-1 to key binding sites in
this region. The approach adopted was to deﬁne HMG I in-
teractions, in combination with AP-1, with the 59-UTR using
recombinant proteins. Then we tested the signiﬁcance of these
ﬁndings by employing nuclear extracts containing endogenous
HMG I/Y prepared from PMA-induced Jurkat extracts, since
phorbol esters are strong inducers of HIV-1 expression.
In the 59-UTR, we have identiﬁed several high-afﬁnity sites
for HMG I/Y, and most of these sites overlap important tran-
scription factor binding sites. Interestingly, similar uncharac-
terized footprints can be seen in a genomic footprint of inte-
grated HIV-1 (see Fig. 2 in reference 5). A number of previous
studies have shown that such an overlap can have a critical role
in regulating gene expression (22, 24, 30, 36). We have focused
on one of these overlapping binding sites, site AP1-3. The
location of this AP-1 binding site, at the boundary of a posi-
tioned nucleosome, suggests that it may play an important role
FIG. 6. HMG I can both selectively inhibit and promote endogenous factor
binding to site AP1-3. (A) The 60% (NH4)2SO4 supernatant fraction, derived
from PMA-induced nuclear extracts (NE), was mock immunodepleted (lanes 2
to 6) or immunodepleted with afﬁnity-puriﬁed antibodies against HMG I/Y
(lanes 7 to 11) or H2A (control, lanes 12 to 16). A mobility gel shift assay, using
site AP1-3, was carried out using these immunodepleted supernatant fractions.
Lanes 2 to 6, 7 to 11, and 12 to 16 received 2, 5, 10, 15, and 20 mgo ft h e
supernatant fraction, respectively. (B) PMA-induced supernatant fractions that
were immunodepleted with either control (H2A) or HMG I afﬁnity-puriﬁed
antibodies were titrated back to a PMA-induced nuclear precipitated fraction.
Lanes 2 to 12 received 7 mg of nuclear (NH4)2SO4-precipitated proteins. Lanes
3 to 7 and lanes 8 to 12 received 5, 10, 20, 30, and 40 mg of H2A- or HMG
I/Y-depleted supernatant fractions, respectively. (C) Increasing amounts of re-
combinant HMG I were added to DNA-binding reactions that received 10 mgo f
uninduced nuclear precipitated extract and a labeled oligonucleotide that con-
tained site AP1-3. Lanes 2 to 6 received 0, 25, 50, 100, and 200 ng of HMG I,
respectively.
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hanced HMG I binding to site AP1-3 using PMA-induced
nuclear extracts but only under in vitro conditions that allow
HMG I binding, i.e., when poly(dG-dC) rather than poly(dI-
dC) is used as competitor DNA. Most importantly, PMA also
induces the synthesis of a new AP-1 complex, and strong bind-
ing of this transcription factor to site AP1-3 is dependent upon
HMG I. Because of this new ﬁnding, previous in vitro binding
studies should be reevaluated. Concerning the role of HMG
I/Y, we cannot rule out the possibility that at least a subset of
these identiﬁed binding sites may have a role in the integration
process.
A major unanswered question concerning the function of
these chromosomal proteins is whether HMG I and Y play the
same role or have different roles. Interestingly, we observed
that HMG I and not HMG Y is strongly induced upon PMA
stimulation of Jurkat cells. This suggests that these proteins
may indeed have different functions. Given that these two
proteins originate from alternative splicing of the same RNA
transcript, this differential regulation must occur via a post-
transcriptional mechanism. Such differential control could, for
example, operate at the level of the splicing event itself, result
from differences in the stability or translational efﬁciency of the
alternatively spliced transcripts, or, perhaps, result from intrin-
sic differences in the stability of the HMG I and HMG Y
proteins (although both proteins appear to be extremely stable
in living cells) (6). A similar selective enhancement of HMG I
protein by tetradecanoyl phorbol acetate was observed in
transformation-resistant JB6 murine cell lines (9). Most inter-
estingly, this same study raised the possibility that HMG Y may
have a role in the transformation process, since they observed
that HMG Y is induced by tumor promoters only in transfor-
mation-sensitive cells. Potentially, the conserved 11-amino-
acid segment absent in HMG Y might alter the quality or the
speciﬁcity of protein-protein interactions with target proteins.
Concerning their DNA-binding activity in Jurkat nuclear ex-
tracts, we also report here another difference between HMG I
and HMG Y. HMG Y is present in both uninduced and in-
duced nuclear extracts and, at least as shown by mobility gel
shift assays, does not bind to DNA when both of these nuclear
extracts are used. Although this may be due to low abundance,
another possible explanation for this is that HMG Y is pos-
translationally modiﬁed in vivo in a differential manner from
HMG I (Banks and Reeves, unpublished data), and it is this
constellation of secondary biochemical modiﬁcations (includ-
ing phosphorylation and others) that inhibits the binding of the
HMG Y isoform protein to DNA (32). Clearly, this hypothesis
will need to be tested.
FIG. 7. Inducible AP-1 complex 3 contains ATF-3. Biotinylated site AP1-3 was incubated with induced or uninduced nuclear extract (NE) (250 mg of total protein),
and the DNA-bound AP-1 factors were isolated as described in Materials and Methods. The isolated proteins were run on an SDS–12% polyacrylamide gel and either
probed with commercial antibodies raised against different AP-1/CREB family members (A) or stained with silver (B). To determine which AP-1/CREB family
members are present initially in uninduced and induced nuclear extracts, 15 mg of unpuriﬁed nuclear extract was also probed with the different antibodies (A) and
stained with silver (B). NE, uninduced Jurkat T cells; PMA-NE, Jurkat T cells stimulated with PMA.
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ferent individual members which are able to dimerize with
each other to form a diverse range of transcription factor
complexes, each capable of recognizing the same or similar
DNA-binding sequences. The mechanisms that operate in the
nucleus to determine which factor actually binds to a regula-
tory site in a promoter are poorly understood. The results
presented here suggest that HMG I may play an important role
in this selection process. We found that in a complex nuclear
extract consisting of a wealth of DNA-binding proteins, a sit-
uation analogous to the environment within the nucleus, HMG
I can selectively promote the binding of an inducible AP-1
factor, ATF-3, to the AP1-3 site (complex 3), relative to the
binding of competing basal DNA-binding proteins. In such a
competition mechanism, the ability of HMG I to increase the
afﬁnity or stability of ATF-3 for site AP1-3 would enable this
factor to compete more effectively with basal factors. The bind-
ing of this inducible AP-1 factor would be further enhanced if
HMG I could selectively and directly inhibit the binding of
basal factors. Indeed, such an inhibition of binding was ob-
served when HMG I was added to uninduced extracts. There-
fore, HMG I can either selectively interfere with or enhance
protein-DNA binding, and which of these events occurs ap-
pears to be partially dependent on the nature of the DNA-
binding protein involved (see below). Precedents exist for such
a mode of differential regulation by the HMG I protein. Pre-
viously, using two different recombinant isoforms of ATF-2,
ATF-2195 and ATF-2192, it was shown that while HMG I could
stimulate ATF-2195 DNA binding, it actually inhibited the
binding of ATF-2192 to the beta interferon promoter. ATF-2192
lacks important amino acid residues involved in HMG I–
ATF-2 interactions (13). Such a striking differential effect was
also observed when the interaction of Oct-1 and Oct-2 with the
octamer sequence was compared (1). HMG I selectively en-
hanced Oct-2 binding while at the same time inhibiting Oct-
1–DNA interactions.
There are at least two, nonmutually exclusive, mechanisms
by which HMG I could enhance ATF-3 binding to site AP1-3
in a PMA-induced nuclear extract. These HMG proteins have
been described as being architectural transcription factors be-
cause they can bend DNA, thereby establishing a particular
DNA conformation that may be more favorable for transcrip-
tion factor binding (6). The binding of several HMG molecules
along a stretch of DNA may even create a DNA scaffold that
can facilitate the formation of large nucleoprotein complexes
via cooperative protein-protein interactions. Such a mecha-
nism operates in the induction of human beta interferon gene
expression (44). Individually, the binding of two HMG I mol-
ecules to positive regulatory domains IV and II enhances ATF-
2/c-Jun and NF-kB binding, respectively, by reversing intrinsic
DNA bends at these factor-binding sites. In combination, these
two HMG proteins facilitate the formation of a highly stable
and sterospeciﬁc transcription factor complex. The selectivity
observed with regard to the enhanced binding of PMA-induc-
ible ATF-3 to site AP1-3 could, in part, be explained by the
generation of a highly speciﬁc DNA structure by HMG I.
Analogous to the human beta interferon gene, it will also be
interesting to examine whether the location of multiple HMG
I binding sites in the 59-UTR contributes to the formation of a
large stable nucleoprotein complex.
Potentially, HMG I could also selectively enhance the bind-
ing of one transcription factor over another by its ability to
interact directly with transcription factors themselves via spe-
ciﬁc protein-protein interaction surfaces. Indeed, stabilization
of the assembled nucleoprotein complex on the human beta
interferon gene enhancer appears to require speciﬁc protein-
protein interactions between HMG I and transcriptional acti-
vators (50). Such protein-protein interactions can also enhance
factor binding in a mechanism that is independent of HMG I’s
interacting with DNA. For example, protein-protein interac-
tions between HMG I and NF-Y (10) and SRF (8) are sufﬁ-
cient for enhancement of their DNA-binding activity, presum-
ably by inducing an active conformation. It has also been
shown that HMG I can, in part, stimulate the binding of ATF-
2/c-Jun to positive regulatory domain IV by promoting the
dimerization reaction. Interestingly, we have observed that
HMG I can enhance Fos-Jun binding to site AP1-1 in nuclear
extracts even though HMG I does not bind to this AP-1 site
(unpublished data).
Our results, using recombinant and nuclear proteins, also
suggest that the second part of the mechanism that promotes
speciﬁc binding of the inducible AP-1 complex to the compos-
ite site AP1-3 is the selective inhibition of binding of basal
DNA-binding proteins by HMG I. Since the binding sites for
HMG I and AP-1 overlap, this competitive inhibition could be
achieved either by direct steric hindrance or by HMG I altering
the conformation of the DNA to a structure that is not com-
patible for basal factor binding. Interestingly, HMG I does not
inhibit the binding of recombinant NF-AT to an adjacent bind-
ing site (Fig. 2 and data not shown). As discussed above, HMG
I can selectively inhibit the DNA-binding activity of ATF-2192
and Oct-1. It has also been reported that HMG I can inhibit
the binding of NF-AT factors to the interleukin-4 promoter
(26). This inhibition of binding, which is reversed by phosphor-
ylation of HMG I, is believed to be important for development
of Th2 cells. Similarly, HMG I (and HMG I-C) can interfere
with the binding of homeodomain proteins to target sequences
(these sequences contain TAAT as a core motif) (3). This
inhibition appears to be due to HMG I-induced conforma-
tional changes in the DNA. Therefore, it appears that HMG I
can modulate gene expression by functioning either as an ac-
tivator or as a repressor. Moreover, we show here that HMG I
can enhance the binding of one DNA-binding protein and
inhibit the binding of another factor even on the same tran-
scription factor-binding site. We also conclude that the ﬁnal
outcome of whether HMG I selectively inhibits or stimulates
transcription factor binding is dependent not only on the na-
ture of the transcriptional activator, but also on a complex
interplay between relative DNA afﬁnities and protein concen-
trations, the location of the HMG binding site with respect to
the factor-binding site, and presumably, the biochemical mod-
iﬁcation status of HMG I.
Transfection-cocultivation experiments with wild-type and
mutant HIV-1 proviral DNAs have show that the three AP-1
sites encompassing the downstream-positioned nucleosome
play a fundamental role in the life cycle of the virus. Sites
AP1-1 and AP1-2 (Fig. 2) play a critical role on HIV-1 repli-
cation, while site AP1-3 appears to be important for transcrip-
tional activation in response to a broad range of external stim-
uli under different physiological conditions (37, 38, 41, 45).
This site is highly conserved among HIV-1 isolates. Studies
employing supershift analysis have reported that AP-1 com-
plexes that interact with this site contain c-Fos and Jun D as
well as CREB, ATF-1, and ATF-2 (38, 41). In contrast to these
published results, using a more stringent assay, we have found
that ATF-3 is a major component that interacts with site
AP1-3. One possible reason for this discrepancy is that under
our DNA-binding conditions, HMG I is able to interact with
the DNA, thereby inﬂuencing the composition of bound tran-
scription factors.
The association of ATF-3 with site AP1-3 is consistent with
the observation that this site responds to a broad range of
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within2hb ymany treatments like different growth-stimulating
factors, PMA, and cytokines as well as physiological stresses,
including tissue damage (reviewed in reference 20). Consistent
with these observations, analysis of the 59-ﬂanking region of
the ATF-3 gene revealed inducible AP-1, ATF/CRE, and
NF-kB binding sites. Interestingly, E2F and Myc/Max binding
sites were also identiﬁed, raising the possibility that ATF-3
may be regulated in a cell cycle-dependent manner (31).
ATF-3 functions as an activator when it heterodimerizes with
Jun family members (20). The results of this study show that
neither c-Jun nor Jun D partners ATF-3 to assemble PMA-
inducible complex 3. To date, no physiologically important
target genes mediating the activation of signaling pathways
involving ATF-3 have been identiﬁed. Interestingly, we also
have identiﬁed the Fos-related antigen Fra-1 as a factor that
binds to site AP1-3 in uninduced nuclear extracts. Consistent
with this observation, it has been reported that, in contrast to
c-Fos, the fra-1 gene is expressed at high levels in proliferating
cells (27).
The results of this study raise the possibility that HMG I may
play an important role in HIV-1 expression. Preliminary ex-
periments have shown that antisense HMG I RNA can reduce
the expression of HIV reporter constructs (data not shown).
Other viruses might employ this strategy to ensure their prop-
agation in host cells, especially if critical transcription factors
have a low afﬁnity for important viral promoter elements.
HMG I has been shown to stimulate Tst-1/Oct-6 binding to an
important regulatory element that mediates the activation of
human papovavirus JC virus gene expression (29). The latency-
active promoter 2 in herpes simplex virus type 1 (which be-
comes a nucleosomal episome) contains a stretch of 23 thymi-
dine residues critical for promoter activity, which interacts with
HMG I/Y. In vitro, the binding of HMG I/Y to this promoter
element enhances the binding of SP-1 to neighboring binding
sites (17). With regard to chromatin disruption and the acti-
vation of HIV-1 transcription, based on the location of site
AP1-3 at the boundary of the positioned nucleosome, we pos-
tulate that HMG I may play a fundamental role in the chro-
matin remodeling process. The association of HMG I with the
nucleosomal dyad may also contribute to this disruption pro-
cess (40). We are currently testing this hypothesis.
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